Professional Documents
Culture Documents
Comprehending Key Market Drivers Gauging Competitive Intelligence Identifying Key Growth Areas and Opportunities Understanding Geographic Relevance to Product Knowing Regional Market Sizes and Growth Opportunities and Restraints Keeping Tab on Emerging Technologies Equity Analysis Tapping New Markets
RITMIR001: ADME/Tox Technologies A Market Insight Report, Jan 2014 RI Technologies - www.researchimpact.com
Sample Page - 1
Analytics and data presented in this report pertain to several parameters such as
Global And Regional Market Sizes, Market Shares, Market Trends Product (Global And Regional) Market Sizes, Market Shares, Market Trends Technology Trends Corporate Intelligence Key Companies By Sales, Brands, Products Consumer Behavioral Patterns Other Strategic Business Affecting Data
RITMIR001: ADME/Tox Technologies A Market Insight Report, Jan 2014 RI Technologies - www.researchimpact.com
Sample Page - 2
Research Methodology
RI Technologies publishes business intelligence reports by going through a cycle of diligent research and analysis activity. Research is done using both online and offline resources. The study outline of this report is sketched on the following lines global market analysis, regional market analysis, product segmentation, Global and regional market analysis by product segment, market trends, M&A, R&D, competitive landscape, technology trends, and other key drivers. Current data helps in analyzing the future of the industry and is also helpful for doing market evaluations, and estimating the market size for the future. This report is uniquely researched and the methodology includes:
Need and Scope of Study Product Definitions Segmental Analysis Regional Analysis Exclusive Data Analytics Corporate Intelligence Feedback
Right from concept to final compilation of this report, both primary and secondary research methods are applied. We have provided exclusive feedback forms/pre-release questionnaires for this report to use the information for authentication of our own findings. Secondary research includes government publications, investment research reports, web based surveys, website information of both companies and markets, and other offline resources such as print publications and CDs. Our compilation of easy to navigate PDF reports are essential value addition resources for leading and growing companies.
RITMIR001: ADME/Tox Technologies A Market Insight Report, Jan 2014 RI Technologies - www.researchimpact.com
Sample Page - 3
Absorption
Absorption determines the compounds bioavailability. Oral delivery is the most desirable route of drug administration. The effective gastrointestinal absorption of an orally administered drug is one of the key factors for its bioavailability, and the rate of Absorption mainly depends upon the surface area of the intestine.
Distribution
Distribution refers to the passage of the drug to the every tissue of the body depending upon the particle size by the process of filtration, diffusion and osmosis. The extent of drug distributed in the body is referred to as Volume of Distribution.
Metabolism
The definition of metabolism is the processing of a particular substance inside the living body. Compounds start to disintegrate immediately after entering the living body. A substantial part of the small-molecule drug metabolism is performed within the liver by redox enzymes. These redox enzymes are known as cytochrome P450 enzymes. When the process of metabolism takes place, the original compound which has entered the body, gets transformed into new compounds.
RITMIR001: ADME/Tox Technologies A Market Insight Report, Jan 2014 RI Technologies - www.researchimpact.com
Sample Page - 4
The new compounds are called metabolites. The metabolites soon become pharmacologically inactive. At that point in time, metabolism inhibits the dose of the original drug that was dispensed. As this deactivation process advances there is a reduction of the effects on the body. Intermittently, it will be observed, that the metabolites could be pharmacologically active. The metabolites may become more active than the original drug that was administered.
Excretion
Excretion or elimination may be described as the process of discharging metabolic waste from the organs, tissues or blood. The compounds and the metabolites of the compounds have to be necessarily eliminated from the body. The process is termed as excretion. The excretion via kidneys is through urine. The waste matter eliminated via the bowels is feces. It is imperative that excretion is thorough. If not, the aggregation of foreign substances tends to negatively affect regular and functional metabolism. Drug excretion takes place via three sites. They are as follows: 1. The most essential site is the kidneys through which drug excretion occurs. The waste matter is eliminated through the urine. 2. Fecal excretion and biliary excretion, that is, relating to bile, is initiated in the liver. The waste matter then is transported through the guts and the last part of the process is the excretion through the feces. 3. The third method of excretion is via the lungs. The lungs are used by the body to eliminate organic anesthetic gases.
Toxicity
Toxicity refers to the degree to what extent a substance or matter or the combination of matter can endanger humans. There are two basic toxicities - chronic toxicity and acute toxicity. Chronic toxicity harms over an extended period, is generally repeated and continues. Acute toxicity causes harmful effects over a short period of time.
RITMIR001: ADME/Tox Technologies A Market Insight Report, Jan 2014 RI Technologies - www.researchimpact.com
Sample Page - 5
High Throughput Screening (HTS) Primary Screening Secondary Screening Biochemical Assays Cell-based Assays High Content Screening
RITMIR001: ADME/Tox Technologies A Market Insight Report, Jan 2014 RI Technologies - www.researchimpact.com
Sample Page - 6
RITMIR001: ADME/Tox Technologies A Market Insight Report, Jan 2014 RI Technologies - www.researchimpact.com
Sample Page - 7
RITMIR001: ADME/Tox Technologies A Market Insight Report, Jan 2014 RI Technologies - www.researchimpact.com
Sample Page - 8
RITMIR001: ADME/Tox Technologies A Market Insight Report, Jan 2014 RI Technologies - www.researchimpact.com
Sample Page - 9
Exhibit 2. In Vitro ADME/Tox Technologies Global Value Market Estimations and Predictions (20052020) in US$ Million for United States, Europe, Asia-Pacific, Canada and Rest of World
RITMIR001: ADME/Tox Technologies A Market Insight Report, Jan 2014 RI Technologies - www.researchimpact.com
Sample Page - 10
RITMIR001: ADME/Tox Technologies A Market Insight Report, Jan 2014 RI Technologies - www.researchimpact.com
Sample Page - 11
RITMIR001: ADME/Tox Technologies A Market Insight Report, Jan 2014 RI Technologies - www.researchimpact.com
Sample Page - 12
RITMIR001: ADME/Tox Technologies A Market Insight Report, Jan 2014 RI Technologies - www.researchimpact.com
Sample Page - 13
RITMIR001: ADME/Tox Technologies A Market Insight Report, Jan 2014 RI Technologies - www.researchimpact.com
Sample Page - 14
Exhibit 4. Pharmaceutical Cell-Based Screening Global Value Market Estimations and Predictions (2005-2020) in US$ Billion
RITMIR001: ADME/Tox Technologies A Market Insight Report, Jan 2014 RI Technologies - www.researchimpact.com
Sample Page - 15
RITMIR001: ADME/Tox Technologies A Market Insight Report, Jan 2014 RI Technologies - www.researchimpact.com
Sample Page - 16
Exhibit 5. Pharmaceutical Contract Research United States Value Market Estimations and Predictions (2005-2020) in US$ Billion
RITMIR001: ADME/Tox Technologies A Market Insight Report, Jan 2014 RI Technologies - www.researchimpact.com
Sample Page - 17
RITMIR001: ADME/Tox Technologies A Market Insight Report, Jan 2014 RI Technologies - www.researchimpact.com
Sample Page - 18
Europe trails behind in biotechnology after the United States due to the continents several systemic causes, rather than simply institutional failures. Though Europe has many research institutes and universities, the region does not attract foreign investments. European biotechnology industry relies heavily on research done in the US. Exhibit 6. ADME/Tox Technologies German Value Market Estimations and Predictions (2005-2020) in US$ Million for In Vivo, In Vitro and In Silico
RITMIR001: ADME/Tox Technologies A Market Insight Report, Jan 2014 RI Technologies - www.researchimpact.com
Sample Page - 19
RITMIR001: ADME/Tox Technologies A Market Insight Report, Jan 2014 RI Technologies - www.researchimpact.com
Sample Page - 20
RITMIR001: ADME/Tox Technologies A Market Insight Report, Jan 2014 RI Technologies - www.researchimpact.com
Sample Page - 21
Exhibit 7. Drug Development Cost - Estimations and Predictions (2005-2020) in US$ Million
Year 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 CAGR%
RIT Figures, 2013
Pre-Clinical XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX
Phase I XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX
Phase II XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX
Phase III XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX
Total XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX
US$ Million
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2019
2020
Pre-Clinical
Phase I
Phase II
RITMIR001: ADME/Tox Technologies A Market Insight Report, Jan 2014 RI Technologies - www.researchimpact.com
Sample Page - 22
RITMIR001: ADME/Tox Technologies A Market Insight Report, Jan 2014 RI Technologies - www.researchimpact.com
Sample Page - 23
Analysis by Segment
Exhibit 9. In Silico ADME/Tox Global Value Market Estimations and Predictions (2005-2020) in US$ Million for Organ and Tissue Cells, Cellular Networks, and Whole Cells
Year/Segment 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 %CAGR
RIT Figures, 2013
Organ & Tissue Cells XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX
Cellular Networks XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX
Whole Cells XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX
Total XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX
US$ Million
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
Cellular Networks
Whole Cells
RITMIR001: ADME/Tox Technologies A Market Insight Report, Jan 2014 RI Technologies - www.researchimpact.com
Sample Page - 24
About RI Technologies
RI Technologies is a premier source of market research on the Biotechnology & Healthcare sector. We emphasize on factual insights and forecasts with maximum global coverage. RI Technologies is constantly monitoring the biotechnology & Healthcare industry, tracking market trends, and forecasting industry based on specialized analysis. The life sciences sector is an ever growing marketplace with emerging technologies in areas of discovery, design and development.
Gauging Competitive Intelligence Identifying Key Growth Areas and Opportunities Understanding Geographic Relevance to Product Knowing Regional Market Sizes and Growth Opportunities and Restraints Keeping Tab on Emerging Technologies Equity Analysis Tapping New Markets
RITMIR001: ADME/Tox Technologies A Market Insight Report, Jan 2014 RI Technologies - www.researchimpact.com
Sample Page - 25
COPYRIGHT
The copyright and publication rights to all RI Technologies' reports and other products are the property of the company. Plagiarism of any kind accounts to violation of copyright laws. Any type of reproduction of the material without express permission is not allowed. The buyer, under no circumstances, shall license, resell or repackage, or sell data without prior permission of the company.
DISCLAIMER
RI Technologies sells content in good faith. The company is not liable to the buyer for any implications arising out of the usage of data for any particular purpose. The company makes no representations or warranties for the accuracy or completeness of the data. While extreme caution and effort is practiced for data compilation and presentation, the company does not accept any responsibility for findings in the study which are a cumulative effort of primary and secondary research resources. The studies do not endorse or promote any product or company. RI Technologies, its affiliates, partners, distributors, and contractors are not liable for inaccuracies or incompleteness of the reports. User discretion is recommended for the usage of the data.
RITMIR001: ADME/Tox Technologies A Market Insight Report, Jan 2014 RI Technologies - www.researchimpact.com
Sample Page - 26